Contact
searchSearch
HMP Global
Login

HRR

Videos

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer
12/12/2023
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of...
12/12/2023
Oncology
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre
Videos
Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer
11/02/2023
Shahneen Sandhu, MBBS
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational...
11/02/2023
Oncology
Elena Castro, MD, PhD Hospital Universitario 12 de Octubre
Videos
Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
11/01/2023
Elena Castro, MD, PhD
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final...
11/01/2023
Oncology
Eleni Efstathiou, MD, Houston Methodist Cancer Center
Videos
Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations
02/27/2023
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary...
02/27/2023
Oncology
Diana Osorio, MD, MPH, MD Anderson Cancer Center
Videos
Targeting BRAF V600E in Pediatric Cervicomedullary Ganglioglioma
09/18/2026
Diana Osorio, MD, MPH
Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...
Diana Osorio, MD, MPH, discusses the clinical significance of BRAF V600E in pediatric cervicomedullary ganglioglioma, highlighting the role of molecular profiling in guiding BRAF/MEK-targeted therapy and the practical considerations of...
Diana Osorio, MD, MPH, discusses...
09/18/2026
Oncology
Geoffrey Ku, MD
Videos
Zanidatamab-Based Regimens Redefine First-Line Treatment of HER2-Positive Gastroesophageal Adenocarcinoma
09/08/2026
Geoffrey Ku, MD
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses...
09/08/2026
Oncology
Viktor Grünwald, MD, PhD
Videos
Nivolumab Plus Ipilimumab Fails to Overcome Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma
09/02/2026
Viktor Grünwald, MD, PhD
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD,...
09/02/2026
Oncology
Allen Khudaverdyan, MD
Videos
Statin-Specific Effects May Influence Immunotherapy Outcomes in Patients With Head and Neck Squamous Cell Carcinoma
09/02/2026
Allen Khudaverdyan, MD
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD,...
09/02/2026
Oncology
Christopher Noel, MD, PhD
Videos
Perioperative Pembrolizumab May Not Be Cost-Effective in Advanced Head and Neck Cancer
09/02/2026
Christopher Noel, MD, PhD
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD,...
09/02/2026
Oncology
Andrew Hahn, MD
Videos
Molecularly Guided Treatment Intensification in Metastatic Prostate Cancer
08/27/2026
Andrew Hahn, MD
Andrew Hahn, MD, discusses a case of de novo metastatic prostate cancer, highlighting how comprehensive molecular profiling can guide treatment intensification with androgen-deprivation therapy, an androgen receptor pathway inhibitor, and...
Andrew Hahn, MD, discusses a case of de novo metastatic prostate cancer, highlighting how comprehensive molecular profiling can guide treatment intensification with androgen-deprivation therapy, an androgen receptor pathway inhibitor, and...
Andrew Hahn, MD, discusses a...
08/27/2026
Oncology
Diwakar Davar, MBBS
Videos
PRAME-Directed T-Cell Receptor Therapy Demonstrates Durable Responses in Advanced Melanoma
08/18/2026
Diwakar Davar, MBBS
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses...
08/18/2026
Oncology
Shubham Pant, MD
Videos
Beyond Chemotherapy: Targeting RAS in Metastatic Pancreatic Cancer
08/17/2026
Shubham Pant, MD
Shubham Pant, MD, explores how emerging RAS-targeted therapies may offer new treatment opportunities for patients with KRAS G12D–mutated metastatic pancreatic cancer.
Shubham Pant, MD, explores how emerging RAS-targeted therapies may offer new treatment opportunities for patients with KRAS G12D–mutated metastatic pancreatic cancer.
Shubham Pant, MD, explores how...
08/17/2026
Oncology
Craig L. Slingluff, Jr., MD
Videos
Long-Term Follow-Up Demonstrates Improved Outcomes With Two-Site Peptide Vaccination in Melanoma
08/12/2026
Craig Slingluff, MD
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses...
08/12/2026
Oncology
Sikander Ailawadhi, MD
Videos
FDA Approval Expands Isatuximab Delivery Options in Multiple Myeloma
08/07/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD,...
08/07/2026
Oncology

News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
Allison Casey
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology

Quizzes

Quiz
Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
Safety and Preliminary Activity of Eganelisib in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
Polycythemia Vera Management Pre-Survey
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 1
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology
OLN

HRR

ALIASES

Human recombination repair

References

Homologous recombination repair (HHR) is a DNA repair mechanism that removes damaged DNA by acting on double-strand breaks, interstrand crosslinks, and other kinds of DNA damage.1 DNA damage is repaired with high fidelity by correcting damage with information copied from a homologous undamaged molecule.2 Defects in HRR are present in some cancers.3

Recent News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
Allison Casey
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use